Do you want to read an article? Please log in or register.
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Lipid-Lowering Drugs
RECOMMENDED
Related content
Lipid-Lowering Drugs
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
JAMA Cardiol.
Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ
doi: 10.1001/jamacardio.
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
Int J Cardiol.
Dufour R, Bergeron J, Gaudet D, Weiss R, Hovingh GK, Qing Z, Yang F, Andisik M, Torri A, Pordy R, Gipe DA
doi: 10.1016/j.ijcard.2016.11.046.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Lancet Diabetes Endocrinol.
Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA
doi: 10.1016/S2213-8587
RECOMMENDED
Hypertension
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Adv Ther
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM
doi: 10.1007/s12325-021-01898-1
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Coll Cardiol.
Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ
doi: 10.1016/j.jacc.2019.12.020.
RECOMMENDED
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis.
Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L
doi: 10.1016/j.atherosclerosis.2020.07.006.
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering DrugsTherapy and Intervention
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Atherosclerosis.
Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C
doi: 10.1016/j.atherosclerosis.
Cardiac Arrest or DeathCardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
Lancet
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM, FAST Study Group.
doi: 10.1016/S0140-6736(20)32234-0
Lipid-Lowering Drugs
Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies
Circulation
Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent RE, Djedjos CS, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators
doi: 10.1161/CIRCULATIONAHA.